DOI: 10.32364/2587-6821-2026-10-2-5
Сolloidal silicon dioxide for the management of atopic dermatitis in adult patients
V.V. Klimov, A.A. Denisov, E.N. Kologrivova, T.V. Koshovkina, N.S. Koshkarova, A.V. Klimov, O.A. Selezneva
Siberian State Medical University, Tomsk, Russian Federation
Background: atopic dermatitis (AD), a chronic and socially significant allergic condition, necessitates objective monitoring for modern therapeutic interventions. The SCORAD index serves as a validated tool for assessing drug efficacy and maintaining clinical control in patients with AD.
Aim: to evaluate the clinical efficacy of colloidal silicon dioxide based on changes in the SCORAD index during AD exacerbations.
Materials and Methods: the study involved 47 patients (aged 20–41 years) with mild to moderate AD. Patients were stratified into three cohorts: a follow-up group (n=20; moderate AD, received colloidal silicon dioxide for 14 days in addition to standard therapy), a comparison group (n=14; moderate AD, standard therapy only), and a control group (n=13; mild AD) formed to assess whether the SCORAD index could serve as a tool for controlling such a reduction in AD inflammatory activity that might raise the question of severity reassessing of the process.
Results: analysis of the integral SCORAD index (an integral parameter that includes several parameters of allergic skin inflammation) demonstrated a statistically significant clinical improvement in patients with moderate AD following the administration of colloidal silicon dioxide. Selective analysis of the SCORAD index components revealed significant reductions in pruritus, resolution of erythema and skin edema, and marked improvement in sleep quality.
Conclusions: due to its proven clinical efficacy and high safety profile, colloidal silicon dioxide is a promising therapeutic enterosorbent for patients with moderate AD. Objective assessment using the SCORAD index confirms that this agent significantly alleviates itching, improves sleep, and resolves mild inflammatory skin manifestations.
Keywords: atopic dermatitis, SCORAD index, colloidal silicon dioxide, clinical efficacy, pruritus reduction.
For citation: Klimov V.V., Denisov A.A., Kologrivova E.N., Koshovkina T.V., Koshkarova N.S., Klimov A.V., Selezneva O.A. Сolloidal silicon dioxide for the management of atopic dermatitis in adult patients. Russian Medical Inquiry. 2026;10(2):95–101 (in Russ.). DOI: 10.32364/2587-6821-2026-10-2-5
About the authors:
Vladimir V. Klimov — Dr. Sc. (Med.), Professor, Head of the Department of Immunology and Allergology, Siberian State Medical University; 2, Moskovsky Trakt, Tomsk, 634050, Russian Federation; ORCID iD 0000-0001-6673-7556
Andrey A. Denisov — Dr. Sc. (Med.), Associate Professor, Professor of the Department of Immunology and Allergology, Siberian State Medical University; 2, Moskovsky Trakt, Tomsk, 634050, Russian Federation; ORCID iD 0000-0001-7592-5284
Elena N. Kologrivova — Dr. Sc. (Med.), Professor of the Department of Immunology and Allergology, Siberian State Medical University; 2, Moskovsky Trakt, Tomsk, 634050, Russian Federation; ORCID iD 0000-0003-1639-4676
Tatyana V. Koshovkina — Dr. Sc. (Med.), Associate Professor of the Department of Immunology and Allergology, Siberian State Medical University; 2, Moskovsky Trakt, Tomsk, 634050, Russian Federation; ORCID iD 0000-0001-7280-1980
Natalya S. Koshkarova — Dr. Sc. (Med.), Associate Professor of the Department of Immunology and Allergology, Siberian State Medical University; 2, Moskovsky Trakt, Tomsk, 634050, Russian Federation; ORCID iD 0000-0002-6032-2402
Andrey V. Klimov — Dr. Sc. (Med.), Associate Professor of the Department of Immunology and Allergology, Siberian State Medical University; 2, Moskovsky Trakt, Tomsk, 634050, Russian Federation; ORCID iD 0000-0002-2776-5834
Olga A. Selezneva — Research Assistant, Department of Immunology and Allergology, Siberian State Medical University; 2, Moskovsky Trakt, Tomsk, 634050, Russian Federation; ORCID iD 0009-0004-2335-3690
Contact information: Vladimir V. Klimov, e-mail: vlklimov54@gmail.com
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interest.
Received 20.02.2026.
Revised 15.03.2026.
Accepted 27.03.2026.
References
1. Stander S. Atopic dermatitis. N Engl J Med. 2021;384:1136–1143. DOI: 10.1056/NEJMra2023911
2. Avena-Woods C. Overview of atopic dermatitis. Am J Manag Care. 2017;23(8):S115–123.
3. Klimov V.V. Textbook of Allergen Tolerance. Switzerland, Cham: Springer Nature. 2022. DOI: 10.1007/978-3-031-04309-3
4. Wen H.C., Czarnowicki T., Noda S. et al. Serum from Asian patients with atopic dermatitis is characterized by TH2/TH22 activation, which is highly correlated with nonlesional skin measures. J Allergy Clin Immunol. 2018;142:324–328.e11. DOI: 10.1016/j.jaci.2018.02.047
5. Banks T.A., Gada S.M. Filaggrin mutations as an archetype for understanding the pathophysiology of atopic dermatitis. J Am Acad Dermatol. 2014;71(3):592–593. DOI: 10.1016/j.jaad.2014.04.075
6. Потекаев Н.Н., Терещенко Г.П., Ханферьян Р.А., Савастенко А.Л. Иммунные механизмы атопического дерматита и новые подходы к таргетной биологической терапии. Медицинский Совет. 2022;3:130–136. DOI: 10.21518/2079-701X-2022-16-3-130-136Potekaev N.N., Tereshchenko G.P., Khanferyan R.A., Savastenko A.L. Immune mechanisms of atopic dermatitis and new approaches to targeted biological therapy. Meditsinskiy Sovet. 2022;16(3):130–136 (in Russ.). DOI: 10.21518/2079-701X-2022-16-3-130-136
7. Tham E.H., Leung D.Y.M. Mechanisms by which atopic dermatitis predisposes to food allergy and the atopic march. Allergy Asthma Immunol Res. 2019;11(1):4–15. DOI: 10.4168/aair.2019.11.1.4
8. Banzon T., Leung D.Y.M., Schneider L.C. Food allergy and atopic dermatitis. J Food Allergy. 2020;2(1):35–38. DOI: 10.2500/jfa.2020.2.200018
9. Thyssen J.P., Halling A.S., Schmid-Grendelmeier P. et al. Comorbidities of atopic dermatitis-what does the evidence say? J Allergy Clin Immunol. 2023;151(5):1155–1162. DOI: 10.1016/j.jaci.2022.12.002
10. Логвинов С.В., Герасимов А.В., Денисов А.А. и др. Морфологические маркеры ремоделирования кожи у пациентов с атопическим дерматитом. Современные проблемы науки и образования. 2015;6.(Электронный ресурс.) URL: https://science-education.ru/ru/article/view?id=23080 (дата обращения: 18.02.2026).Logvinov S.V., Gerasimov A.V., Denisov A.A. et al. Morphological markers of skin remodeling in patients with atopic dermatitis. Modern Problems of Science and Education. 2015;6. (Electronic resource.) URL: https://science-education.ru/ru/article/view?id=23080 (access date: 18.02.2026).
11. Thangam E.B., Jemima E.A., Singh H. et al. The role of histamine and histamine receptors in mast cell-mediated allergy and inflammation: the hunt for new therapeutic targets. Front Immunol. 2018;9:1873. DOI: 10.3389/fimmu.2018.01873
12. Mahmood S.F., Mahmood W.N., Abdalla O.M. et al. Leukotriene Receptor Antagonists for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-analysis. Acta Derm Venereol. 2025;105:adv43140. DOI: 10.2340/actadv.v105.43140
13. Wollenberg A., Christen-Zach S., Taieb A. et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717–2744. DOI: 10.1111/jdv.16892
14. Митковская ОА. Эффективность применения полисорба МП для лечения аллергических заболеваний. Медицина Кыргызстана. 2014;3:32–34.Mitkovskiy O.A. The effectiveness of using Polysorb MP for the treatment of allergic diseases. Medicine of Kyrgyzstan. 2014;3:32–34 (in Russ.).
15. Вавилова В.П., Вавилов А.М., Царькова С.А. и др. Применение кремния диоксида коллоидного (препарат Полисорб МП) при кожных и гастроинтестинальных проявлениях пищевой аллергии. Педиатрия. Consilium Medicum. 2021;2:158–164. DOI: 10.26442/26586630.2021.2.200967Vavilova V.P., Vavilov A.M., Tsarkova S.A. et al. Colloidal silicon dioxide use (Polisorb MP) at food allergy skin and gastrointestinal manifestations. Pediatrics. Consilium Medicum. 2021;2:158–164 (in Russ.). DOI: 10.26442/26586630.2021.2.200967
16. Thijs J.L., De Bruin-Weller M.S., Hijnen D. Current and future biomarkers in atopic dermatitis. Immunol Allergy Clin N Am. 2017;37:51–61. DOI: 10.1016/j.iac.2016.08.008
17. Renert-Yuval Y., Thyssen J.P., Bissonnette R. et al. Biomarkers in atopic dermatitis-a review on behalf of the International Eczema Council. J Allergy Clin Immunol. 2021;147(4):1174–1190.e1. DOI: 10.1016/j.jaci.2021.01.013
18. Карамова А.Э., Чикин В.В., Знаменская Л.Ф., Аулова К.М. Оценка степени тяжести атопического дерматита — стандартизованные индексы тяжести SCORAD и EASI. Вестник дерматологии и венерологии. 2022;98(3):53–60. DOI: 10.25208/vdv1335ВKaramova A.E., Chikin V.V., Znamenskaya L.F., Aulova K.M. Assessment of the severity of atopic dermatitis — SCORAD and EASI. Vestnik Dermatologii i Venerologii. 2022;98(3):53–60 (in Russ.). DOI: 10.25208/vdv1335
19. Oranje A.P. Practical issues on interpretation of scoring atopic dermatitis: SCORAD Index, objective SCORAD, patient-oriented SCORAD and three-item severity score. Curr Probl Dermatol. 2011;41:149–155. DOI: 10.1159/000323308
20. Voisin T., Bouvier A., Chiu I.V. Neuro-immune interactions in allergic diseases: novel targets for therapeutics. Int Immunol. 2017;29(6):247–461. DOI: 10.1093/intimm/dxx040
21. Carlton S.M. Nociceptive primary afferents: they have a mind of their own. J Physiol. 2014;592(16):3403–3411. DOI: 10.1113/jphysiol.2013.269654
22. Arzoo Puri. Collodial Silicon Dioxide — Properties and Applcations. (Electronic resource.) URl: https://www.azonano.com/article.aspx?ArticleID=6523 (access date: 18.02.2026).
23. Гончаренко А.Ю., Верткин А.Л., Кнорринг Г.Ю. Опыт и перспективы применения комбинированных энтеросорбентов в практике гастроэнтеролога. Медицинский совет. 2025;19(15):171–181. DOI: 10.21518/ms2025-361Goncharenko A.Yu., Vertkin A.L., Knorring G.Yu. Experience and prospects for the use of combination enterosorbents in the practice of gastroenterologists. Meditsinskiy Sovet. 2025;19(15):171–181 (in Russ.). DOI: 10.21518/ms2025-361
24. Do B. Is Colloidal Silicon Dioxide Safe? DrFormulas Research. (Electronic resource.) URL: https://drformulas.com/products/mini-hand-sanitizer-bulk (access date: 18.02.2026).
25. Nafisi S., Samadi N., Houshiar M., Maibach G. Mesoporous silica nanoparticles for enhanced lidocaine skin delivery. Int J Pharmac. 2018;550(1-2):325–332. DOI: 10.1016/j.ijpharm.2018.08.004
26. Tran D.T., Majerová D., Veselý M. et al. On the mechanism of colloidal silica action to improve flow properties of pharmaceutical excipients. Int J Pharm. 2019;556:383–394. DOI: 10.1016/j.ijpharm.2018.11.066
27. Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICА. М.: МедиаСфера; 2002.Rebrova O.Yu. Statistical Analysis of Medical Data. Application of the STATISTICA Application Package. Moscow: MediaSfera; 2002 (in Russ.).
28. Araújo L.A., Addor F., Campos P.M. Use of silicon for skin and hair care: an approach of chemical forms available and efficacy. An Bras Dermatol. 2016;91(3):331–335. DOI: 10.1590/abd1806-4841.20163986
29. Лыткина Е.А., Потекаев Н.Н., Билалова У.Г. и др. Качество жизни больных атопическим дерматитом и приверженность к наружной терапии. Клиническая дерматология и венерология. 2011;9(1):45–48.Lytkina E.A., Potekaev N.N., Bilalova U.G. et al. The quality of life of the patients presenting with atopic dermatitis and their compliance with external therapy. Russian Journal of Clinical Dermatology and Venereology. 2011;9(1):45–48 (in Russ.).
This work is licensed under a
Creative Commons «Attribution» 4.0 License.
Previous article
Next article
